1. Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations.
- Author
-
Kunz AN, Begum AA, Wu H, D'Ambrozio JA, Robinson JM, Shafer WM, Bash MC, and Jerse AE
- Subjects
- Animals, DNA Gyrase genetics, DNA Topoisomerase IV genetics, Female, Gonorrhea microbiology, Gonorrhea pathology, Macrolides pharmacology, Mice, Mice, Inbred BALB C, Neisseria gonorrhoeae genetics, Neisseria gonorrhoeae growth & development, Virulence, Anti-Bacterial Agents pharmacology, Drug Resistance, Bacterial, Fluoroquinolones pharmacology, Mutation, Neisseria gonorrhoeae drug effects, Neisseria gonorrhoeae physiology
- Abstract
Background: Quinolone-resistant Neisseria gonorrhoeae (QRNG) arise from mutations in gyrA (intermediate resistance) or gyrA and parC (resistance). Here we tested the consequence of commonly isolated gyrA(91/95) and parC86 mutations on gonococcal fitness., Methods: Mutant gyrA(91/95) and parC86 alleles were introduced into wild-type gonococci or an isogenic mutant that is resistant to macrolides due to an mtrR(-79) mutation. Wild-type and mutant bacteria were compared for growth in vitro and in competitive murine infection., Results: In vitro growth was reduced with increasing numbers of mutations. Interestingly, the gyrA(91/95) mutation conferred an in vivo fitness benefit to wild-type and mtrR(-79) mutant gonococci. The gyrA(91/95), parC86 mutant, in contrast, showed a slight fitness defect in vivo, and the gyrA(91/95), parC86, mtrR(-79) mutant was markedly less fit relative to the parent strains. A ciprofloxacin-resistant (Cip(R)) mutant was selected during infection with the gyrA(91/95), parC86, mtrR(-79) mutant in which the mtrR(-79) mutation was repaired and the gyrA(91) mutation was altered. This in vivo-selected mutant grew as well as the wild-type strain in vitro., Conclusions: gyrA(91/95) mutations may contribute to the spread of QRNG. Further acquisition of a parC86 mutation abrogates this fitness advantage; however, compensatory mutations can occur that restore in vivo fitness and maintain Cip(R).
- Published
- 2012
- Full Text
- View/download PDF